Search

Your search keyword '"Krzakowski M"' showing total 40 results
Start Over Author "Krzakowski M" Database OpenAIRE
40 results on '"Krzakowski M"'

2. Carboplatin and paclitaxol (Taxol) as an induction regimen for patients with biopsy-proven stage IIIA N2 non-small cell lung cancer. an EORTC phase II study (EORTC 08958)

Author

O'Brien, ME, Splinter, T, Smit, E.F., Biesma, B., Krzakowski, M, Tjan-Heijnen, VC, Van Bochove, A, Stigt, J, Smid-Geirnaerdt, MJ, Debruyne, C., Legrand, C, Giaccone, G., and VU University medical center

Subjects
Interventional oncology [UMCN 1.5]
Abstract

Item does not contain fulltext The aim of this study was to document the activity and toxicity of paclitaxel (Taxol)/carboplatin when used as induction chemotherapy in patients with stage IIIA N2 non-small cell lung cancer (NSCLC) prior to definitive local treatment within a large, ongoing comparative study (EORTC 08941). 52 eligible, consenting, chemotherapy-naive patients with NSCLC, median age of 60 years, stage IIIA N2 disease and the ability to tolerate a pneumonectomy received paclitaxel 200 mg/m2 as a 3-h infusion followed by carboplatin at an area under the concentration curve (AUC) of 6 every 3 weeks for three courses. Most patients received three courses. No grade 3/4 anaemia or thrombocytopenia was documented. Over all of the cycles, 6% (3 patients) experienced grade 3 leucopenia while 63% (32/51 patients) experienced grade 3-4 neutropenia. There was 1 patient (2%) with febrile neutropenia, no early or toxic deaths and no hypersensitivity reactions. Severe non-haematological toxicity was uncommon, with the exception of grade 3 alopecia in 39%, lethargy in 8% and myalgia in 6%. Of the eligible patients (n=52), there was one complete response (CR) and 32 partial responses (PR), resulting in a response rate of 64% (95% Confidence Interval (CI) 49%-76%). Of the 15 eligible patients randomised to surgery after induction chemotherapy, 3 patients did not receive surgery and 2 patients (n=12) had no tumour in the mediastinal nodes (17%). Resections were considered complete in 2 of the 12. Median survival for all eligible patients (n=52) was 20.5 months (95% CI 16.1-31.2), with an estimated 1-year survival rate of 68.5% (95% CI 55.2-81.7). In patients with N2 stage IIIA NSCLC, paclitaxel/carboplatin is an active and very well-tolerated induction regimen.

Published
2003

3. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial

Author

Reck, M, Kaiser, R, Mellemgaard, A, Douillard, Jy, Orlov, S, Krzakowski, M, von Pawel, J, Gottfried, M, Bondarenko, I, Liao, M, Gann, Cn, Barrueco, J, Gaschler Markefski, B, Novello, Silvia, and LUME Lung, 1 Study Group

Subjects
Male, medicine.medical_specialty, Asia, Indoles, Lung Neoplasms, Time Factors, Bevacizumab, medicine.medical_treatment, Adenocarcinoma of Lung, Docetaxel, Kaplan-Meier Estimate, Adenocarcinoma, Placebo, Gastroenterology, Disease-Free Survival, chemistry.chemical_compound, South Africa, Double-Blind Method, Risk Factors, Internal medicine, Carcinoma, Non-Small-Cell Lung, Antineoplastic Combined Chemotherapy Protocols, medicine, Clinical endpoint, Odds Ratio, Humans, Lung cancer, Protein Kinase Inhibitors, Aged, Neoplasm Staging, Proportional Hazards Models, Chemotherapy, Intention-to-treat analysis, business.industry, Middle Aged, medicine.disease, Surgery, Europe, Treatment Outcome, Oncology, chemistry, Disease Progression, Nintedanib, Female, Taxoids, business, medicine.drug
Abstract

Summary Background The phase 3 LUME-Lung 1 study assessed the efficacy and safety of docetaxel plus nintedanib as second-line therapy for non-small-cell lung cancer (NSCLC). Methods Patients from 211 centres in 27 countries with stage IIIB/IV recurrent NSCLC progressing after first-line chemotherapy, stratified by ECOG performance status, previous bevacizumab treatment, histology, and presence of brain metastases, were allocated (by computer-generated sequence through an interactive third-party system, in 1:1 ratio), to receive docetaxel 75 mg/m 2 by intravenous infusion on day 1 plus either nintedanib 200 mg orally twice daily or matching placebo on days 2–21, every 3 weeks until unacceptable adverse events or disease progression. Investigators and patients were masked to assignment. The primary endpoint was progression-free survival (PFS) by independent central review, analysed by intention to treat after 714 events in all patients. The key secondary endpoint was overall survival, analysed by intention to treat after 1121 events had occurred, in a prespecified stepwise order: first in patients with adenocarcinoma who progressed within 9 months after start of first-line therapy, then in all patients with adenocarcinoma, then in all patients. This trial is registered with ClinicalTrials.gov, number NCT00805194. Findings Between Dec 23, 2008, and Feb 9, 2011, 655 patients were randomly assigned to receive docetaxel plus nintedanib and 659 to receive docetaxel plus placebo. The primary analysis was done after a median follow-up of 7·1 months (IQR 3·8–11·0). PFS was significantly improved in the docetaxel plus nintedanib group compared with the docetaxel plus placebo group (median 3·4 months [95% CI 2·9–3·9] vs 2·7 months [2·6–2·8]; hazard ratio [HR] 0·79 [95% CI 0·68–0·92], p=0·0019). After a median follow-up of 31·7 months (IQR 27·8–36·1), overall survival was significantly improved for patients with adenocarcinoma histology who progressed within 9 months after start of first-line treatment in the docetaxel plus nintedanib group (206 patients) compared with those in the docetaxel plus placebo group (199 patients; median 10·9 months [95% CI 8·5–12·6] vs 7·9 months [6·7–9·1]; HR 0·75 [95% CI 0·60–0·92], p=0·0073). Similar results were noted for all patients with adenocarcinoma histology (322 patients in the docetaxel plus nintedanib group and 336 in the docetaxel plus placebo group; median overall survival 12·6 months [95% CI 10·6–15·1] vs 10·3 months [95% CI 8·6–12·2]; HR 0·83 [95% CI 0·70–0·99], p=0·0359), but not in the total study population (median 10·1 months [95% CI 8·8–11·2] vs 9·1 months [8·4–10·4]; HR 0·94, 95% CI 0·83–1·05, p=0·2720). Grade 3 or worse adverse events that were more common in the docetaxel plus nintedanib group than in the docetaxel plus placebo group were diarrhoea (43 [6·6%] of 652 vs 17 [2·6%] of 655), reversible increases in alanine aminotransferase (51 [7·8%] vs six [0·9%]), and reversible increases in aspartate aminotransferase (22 [3·4%] vs three [0·5%]). 35 patients in the docetaxel plus nintedanib group and 25 in the docetaxel plus placebo group died of adverse events possibly unrelated to disease progression; the most common of these events were sepsis (five with docetaxel plus nintedanib vs one with docetaxel plus placebo), pneumonia (two vs seven), respiratory failure (four vs none), and pulmonary embolism (none vs three). Interpretation Nintedanib in combination with docetaxel is an effective second-line option for patients with advanced NSCLC previously treated with one line of platinum-based therapy, especially for patients with adenocarcinoma. Funding Boehringer Ingelheim.

Published
2014

4. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial

Author

Butts C, Ma, Socinski, Pl, Mitchell, Thatcher N, Havel L, Krzakowski M, Nawrocki S, Te, Ciuleanu, Bosquée L, Jm, Trigo, Spira A, Tremblay L, Nyman J, Ramlau R, Wickart-Johansson G, Ellis P, Gladkov O, Jr, Pereira, We, Eberhardt, Helwig C, Andreas Schröder, Fa, Shepherd, and Start, On Behalf Of The Trial Team

Subjects
Adult, Male, medicine.medical_specialty, Lung Neoplasms, Population, Medizin, Placebo, Cancer Vaccines, Gastroenterology, law.invention, Double-Blind Method, Randomized controlled trial, Maintenance therapy, law, Carcinoma, Non-Small-Cell Lung, Internal medicine, medicine, Clinical endpoint, Humans, Lung cancer, education, Aged, Neoplasm Staging, Aged, 80 and over, education.field_of_study, Membrane Glycoproteins, business.industry, Chemoradiotherapy, Middle Aged, medicine.disease, Surgery, Oncology, Tecemotide (L-BLP25), stage III, non-small-cell lung cancer, START, chemoradiotherapy, phase 3 trial, Tecemotide, Female, business
Abstract

Summary Background Effective maintenance therapies after chemoradiotherapy for lung cancer are lacking. Our aim was to investigate whether the MUC1 antigen-specific cancer immunotherapy tecemotide improves survival in patients with stage III unresectable non-small-cell lung cancer when given as maintenance therapy after chemoradiation. Methods The phase 3 START trial was an international, randomised, double-blind trial that recruited patients with unresectable stage III non-small-cell lung cancer who had completed chemoradiotherapy within the 4–12 week window before randomisation and received confirmation of stable disease or objective response. Patients were stratified by stage (IIIA vs IIIB), response to chemoradiotherapy (stable disease vs objective response), delivery of chemoradiotherapy (concurrent vs sequential), and region using block randomisation, and were randomly assigned (2:1, double-blind) by a central interactive voice randomisation system to either tecemotide or placebo. Injections of tecemotide (806 μg lipopeptide) or placebo were given every week for 8 weeks, and then every 6 weeks until disease progression or withdrawal. Cyclophosphamide 300 mg/m 2 (before tecemotide) or saline (before placebo) was given once before the first study drug administration. The primary endpoint was overall survival in a modified intention-to-treat population. This study is registered with ClinicalTrials.gov, number NCT00409188. Findings From Feb 22, 2007, to Nov 15, 2011, 1513 patients were randomly assigned (1006 to tecemotide and 507 to placebo). 274 patients were excluded from the primary analysis population as a result of a clinical hold, resulting in analysis of 829 patients in the tecemotide group and 410 in the placebo group in the modified intention-to-treat population. Median overall survival was 25·6 months (95% CI 22·5–29·2) with tecemotide versus 22·3 months (19·6–25·5) with placebo (adjusted HR 0·88, 0·75–1·03; p=0·123). In the patients who received previous concurrent chemoradiotherapy, median overall survival for the 538 (65%) of 829 patients assigned to tecemotide was 30·8 months (95% CI 25·6–36·8) compared with 20·6 months (17·4–23·9) for the 268 (65%) of 410 patients assigned to placebo (adjusted HR 0·78, 0·64–0·95; p=0·016). In patients who received previous sequential chemoradiotherapy, overall survival did not differ between the 291 (35%) patients in the tecemotide group and the 142 (35%) patients in the placebo group (19·4 months [95% CI 17·6–23·1] vs 24·6 months [18·8–33·0], respectively; adjusted HR 1·12, 0·87–1·44; p=0·38). Grade 3–4 adverse events seen with a greater than 2% frequency with tecemotide were dyspnoea (49 [5%] of 1024 patients in the tecemotide group vs 21 [4%] of 477 patients in the placebo group), metastases to central nervous system (29 [3%] vs 6 [1%]), and pneumonia (23 [2%] vs 12 [3%]). Serious adverse events with a greater than 2% frequency with tecemotide were pneumonia (30 [3%] in the tecemotide group vs 14 [3%] in the placebo group), dyspnoea (29 [3%] vs 13 [3%]), and metastases to central nervous system (32 [3%] vs 9 [2%]). Serious immune-related adverse events did not differ between groups. Interpretation We found no significant difference in overall survival with the administration of tecemotide after chemoradiotherapy compared with placebo for all patients with unresectable stage III non-small-cell lung cancer. However, tecemotide might have a role for patients who initially receive concurrent chemoradiotherapy, and further study in this population is warranted. Funding Merck KGaA (Darmstadt, Germany).

Published
2014

5. Carpal tunnel syndrome and musculoskeletal symptoms in postmenopausal women with early breast cancer treated with exemestane or tamoxifen after 2-3 years of tamoxifen: a retrospective analysis of the Intergroup Exemestane Study

Author

Mieog, Js, Morden, Jp, Bliss, Jm, Coombes, Rc, van de Velde CJ, IES Steering Committee: Delozier, T, Veronesi, A, Vrdoljak, E, Monnier, A, Coombes, C, Nagykalnai, T, Roumen, Rm, Utracka Hutka, B, Pluzanska, A, Porpiglia, M, Genta, F, Benedetto, Chiara, Sozzani, P, Steiner, M, Rubinov, R, Leviov, M, Semiglazov, V, Fox, J, Mayordomo, Ji, Cervek, J, Sleeboom, Hp, Jassem, J, Hinton, Cp, Paulsen, Th, Guleng, Rj, Fein, L, Gutulescu, N, Florián, J, Rosso, R, Rutgers, Ej, Krzakowski, M, Pienkowski, T, Krajina, Z, Siffnerova, H, Pawlicki, M, Drosik, K, Wagnerowa, M, Brunt, M, Vukelja, S, Mitrowic, L, Cataliotti, L, Karnicka Mlodkowska, H, Bonnefoi, H, Tilch, G, Chollet, P, Patel, A, Kamby, C, Giustini, L, Acito, L, Mouridsen, H, Roche, H, De Lafontan, B, Tomczak, P, Petruzelka, L, Lortholary, A, Pacquola, Mg, Skene, A, Rici, S, Michelotti, A, Ghilezan, N, Stewart, A, Beauduin, M, Andersen, J, Vassilaros, S, Celio, L, Bajetta, E, Bastús, R, Marsland, T, Paridaens, R, Tzekova, V, Lichtenegger, W, Piersma, H, Jones, S, Holmberg, S, Verhoeven, D, Hill, A, Porcile, G, Bruno, Mf, Chernozemski, I, Coleman, R, Jadeja, J, Cohn, A, Merlano, M, Perroni, D, Di Costanzo, F, Van Bochove, A, Gerrits, Ma, Malec, V, Balil, A, Mendiola, C, Dodwell, D, Knox, R, Horgan, K, Joannides, T, Leonard, Rc, Cawthorn, Sj, Ghosh, C, Cantrell, J, Campos, D, Orti, R, Diedrich, K, Aas, H, Barnadas, A, Vila, Mm, Makris, A, Anderson, T, Chittor, S, Michel, J, Philip, P, Redmond, P, Mastboom, Wj, Nordenskjöld, B, Simmonds, P, Grieve, Rj, Tomova, A, Piot, G, Borea, G, Ucci, G, Einarsson, E, Nicholson, S, Gardiol, Ea, Kerger, J, Schlosser, J, Namer, M, Pinotti, G, Rutten, Ht, Iversen, T, Nejim, A, Dudov, A, Grundtvig, P, Lang, I, Massidda, B, Van De Velde CH, Gervasio, Mh, Tengrup, I, Tennvall, L, Goodman, S, Modgill, Vk, Vorobiof, Da, Mickiewicz, E, Chirgwin, J, Focan, C, Albin, N, Contu, Aa, Svensson, Jh, Borghede, G, Källström, Ac, Forbes, Jf, Hurtz, Hj, Tubiana Hulin, M, Viens, P, Scanni, A, Arnoldi, E, Nastasi, G, Bottini, A, Alquati, P, Muscat, V, Brincat, S, Holmen, K, Amaral, N, Moreno, I, Trask, C, Robinson, A, Mcintyre, K, Otsuka, A, Hohaus, B, Hoefig, G, Georgoulias, V, Salvagni, S, Bidin, L, Artioli, F, Engan, T, Benedikstsson, Kp, Campbell, I, Harvey, V, Zimbler, H, Mrsic Krmpotic, Z, Canon, Jl, Tchilingirov, Pv, Buser, K, Bolanca, A, Reztke, U, Rhein, U, Jouve, M, Mullins, G, Vesentini, L, Gallo, L, Merlini, L, Decensi, A, Carreca, I, Van Tienhoven, G, Börjesson, B, Hansen, J, Koza, I, Arcusa, A, Inoriza, A, Pelegri, A, Eremin, O, Modiano, Mr, Anthony, S, Donat, D, Richardet, E, Kochli, O, Zeißig, P, Gauch, G, Aabo, K, Fumoleau, P, Erdkamp, Fl, Lovén, L, Jönsson, Pe, Perren, T, Stuart, N, Galindo, E, Marek, Bj, Salmon, Jp, Dohollou, N, Thompson, R, Folco, U, Rosa, A, Tonato, M, Heijmans, Gj, Koralewski, P, Bång, H, Lescure, Ar, Carrato, A, Martin, M, Neave, F, Howell, T, Savin, M, Loesch, D, Hannois, A, Mohr, A, Laube, T, Omar, S, Bonneterre, J, Servent, V, Danese, S, Sertoli, Mr, Butzelaar, Rm, Steller, Ep, Gomez, H, Skoog, P, Alvarez, I, Aguilar, Ea, Giner, Jl, Yosef, Hm, Barrett Lee, P, Buzdar, Au, George, T, Olivaires, J, Vsianska, M, Köhler, U, Lindeløv, B, Toftdahl, Db, Nielsen, Eb, Veyret, C, Castera, D, Kerbrat, P, Vassilaros, P, Yeo, W, Boni, C, Aitini, E, Luporini, G, Herben, Mg, Espelid, H, Dahl, S, Ingvar, C, Meana, A, Pico, C, Garcia, Am, Agrawal, Rk, Gruenberg, D, Nunez de Pierro, A, Gill, G, Nogaret, Jm, Honhon, B, Wassenaar, H, Nielander, R, Warnier, P, Sessa, C, Padrik, P, Guastalla, Jp, Serin, D, Jaubert, D, Dank, M, Given, Fh, Mascia, V, De Fraia, E, Silingardi, V, Conte, Pf, Labianca, R, Tondini, C, Bagnulo, A, Gardani, G, Wils, J, Liem, G, Nuytinck, Jk, Formoe, E, Ambré, T, Alés, J, Aramburo, P, Mansi, J, Graham, J, Joffe, J, Sainsbury, J, Stone, J, Good, Rh, Cartwright, T, Werner, Id, Murray, E, Beith, J, Tigges, Fj, Bojko, P, Sandberg, E, Jensen, B, Lotz, Jp, Carney, D, Shapira, J, Neumann, A, Goldhirsch, A, Dicato, M, de Graaf, H, Maartense, E, Burghouts, J, Cassinello, J, Jones, A, Gaffney, C, Blum, R, Abdi, E, Becquart, D, Dirix, L, Janssens, J, Nmarschner, N, Blaska Jaulerry, B, Prevot, G, Mirah Lev, L, Shani, A, Baruch, Nb, Peretz, T, Gips, M, Cognetti, F, Carlini, P, Nortier, Jw, Huinink D, ten B., Roussel, Jg, Unneberg, K, Kylberg, F, Hovind, H, Nestvold, T, Fogelkvist, R, Due, J, Muller, S, Gilligan, D, Russel, S, Mcaleer, J, Yiangou, C, Foote, L, Schottstaedt, M, Holmes, Fa, Wainstein, R, Contreras, O, Martinez, J, Della Fiorentina, S, Beslija, S, Vermorken, Jb, Thirion, M, Fraikin, J, Castiglione, M, Jäger, W, Fasching, P, Fabriz, H, Neis, K, Kirschbaum, M, Labat, Jp, Dupuis, O, Bernard, J, Datchary, J, Provencal, J, Allain, P, Clerico, M, Lopez, M, Nalli, G, Aspevik, R, Fràguas, A, Curescu, S, Cuevas, Jm, Oltra, A, Bradley, C, Kapoor, R, Akbain, S, Croghan, Mk, Modiano, M, Taetle, R, Beale, P, Gobert, P, Bondue, H, Böhm, R, Møller, Ka, Brettes, Jp, Netter, G, Grogan, L, Klein, B, Botta, M, Barni, S, Van Meerwijk, I, Kåresen, R, Godes, J, Aramburo, A, Jara, C, Zanger, B, Fleagle, Jt, Greenspan, A, Marschke, R, Medgyesy, Dc, Garbo, L., CCA -Cancer Center Amsterdam, and Radiotherapy

Subjects
medicine.medical_specialty, Population, Breast Neoplasms, Disease-Free Survival, chemistry.chemical_compound, Breast cancer, Exemestane, Internal medicine, Surveys and Questionnaires, medicine, Clinical endpoint, Humans, Carpal tunnel syndrome, education, Aged, Retrospective Studies, Aged, 80 and over, education.field_of_study, business.industry, Aromatase Inhibitors, Hazard ratio, Middle Aged, medicine.disease, Carpal Tunnel Syndrome, Surgery, Musculoskeletal Abnormalities, Androstadienes, Postmenopause, Tamoxifen, Treatment Outcome, Oncology, chemistry, Hormonal therapy, Female, business, medicine.drug
Abstract

BACKGROUND: Aromatase inhibitors are more effective than is tamoxifen in prevention of breast-cancer recurrence, but at the expense of increased musculoskeletal side-effects, such as carpal tunnel syndrome. The aim of this study was to assess risk factors and the prognostic value of musculoskeletal symptoms during treatment with the steroidal aromatase inhibitor exemestane or with tamoxifen after 2-3 years of tamoxifen. METHODS: In the Intergroup Exemestane Study, postmenopausal women treated for early invasive breast cancer who remained disease free and on treatment after 2-3 years of tamoxifen were randomised to switch to exemestane or to continue tamoxifen for the remainder of the 5-year period of endocrine treatment. The primary endpoint for this retrospective analysis was occurrence of carpal tunnel syndrome and any musculoskeletal events, analysed in the safety population, which consisted of all patients who had received any trial treatment. As well as case-report forms, questionnaires were distributed retrospectively to gain more details of cases of carpal tunnel syndrome. The relation between musculoskeletal symptoms reported by 6 months from randomisation and survival from 9 months onwards was assessed by Cox proportional hazards models. The trial is registered, number ISRCTN11883920. It has completed accrual and follow-up is continuing for enrolled participants. FINDINGS: After a median follow-up of 91·0 months (IQR 83·0-99·2), carpal tunnel syndrome had been reported for 66 (2·8%) of 2319 patients in the exemestane group compared with 13 (0·6%) of 2338 in the tamoxifen group (odds ratio [OR] 5·23, 99% CI 2·39-11·49; p

Published
2012

7. Analysis of patient-reported outcomes from the LUME-Lung 1 trial: A randomised, double-blind, placebo-controlled, Phase III study of second-line nintedanib in patients with advanced non-small cell lung cancer

Author

Novello, Silvia, Kaiser, R, Mellemgaard, A, Douillard, J, Orlov, S, Krzakowski, M, von Pawel, J, Gottfried, M, Bondarenko, I, Liao, M, Barrueco, J, Gaschler Markefski, B, Griebsch, I, Palmer, M, Reck, M, and LUME Lung, 1 Study Group

Subjects
Adult, Oncology, Quality of life, Cancer Research, medicine.medical_specialty, Indoles, Lung Neoplasms, Lume, Health Status, Nintedanib, Antineoplastic Agents, Docetaxel, Adenocarcinoma, Placebo, law.invention, Placebos, chemistry.chemical_compound, Anti-angiogenesis, Double-Blind Method, Randomized controlled trial, Non-small cell lung cancer, law, Carcinoma, Non-Small-Cell Lung, Surveys and Questionnaires, Internal medicine, medicine, Humans, Lung cancer, neoplasms, Lung, business.industry, medicine.disease, Treatment Outcome, medicine.anatomical_structure, chemistry, Chemotherapy, Adjuvant, Disease Progression, Taxoids, Self Report, business, therapeutics, medicine.drug
Abstract

IntroductionThe LUME-Lung 1 trial (NCT00805194; Study 1199.13) demonstrated a significant overall survival (OS) advantage for nintedanib plus docetaxel compared with placebo plus docetaxel as second-line therapy for patients with advanced non-small cell lung cancer (NSCLC) and adenocarcinoma histology. Patient-reported outcomes (PROs) for symptoms and health-related quality of life (QoL) are reported here.MethodsPROs were assessed at screening, on Day 1 of each 21-day treatment cycle, at the end of active treatment, and at the first follow-up visit. PRO instruments were the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C30 and Lung Cancer-13 supplement, and the EuroQol disease-generic questionnaire (EQ-5D and EQ-VAS). Analyses of PRO items for lung cancer-specific symptoms of cough, dyspnoea and pain were prespecified.ResultsRates of questionnaire completion were high. There was no significant difference in time to deterioration of global health status/QoL, or symptoms of cough, dyspnoea or pain, between the treatment groups for both the overall study population and the adenocarcinoma population. Time to deterioration of some gastrointestinal events was shorter with nintedanib versus placebo. Longitudinal analysis for the adenocarcinoma population showed comparable changes between the groups in symptom scores over time, with numerical differences in favour of nintedanib for cough and pain scales, and significant reductions in some pain items with nintedanib versus placebo. There was no statistically significant difference in EQ-5D or EQ-VAS between the groups.ConclusionThe significant OS benefit observed with the addition of nintedanib to docetaxel therapy was achieved with no detrimental effect on patient self-reported QoL.

Full Text
View/download PDF

11. Role of echocardiography in monitoring of cardiac toxicity of cancer pharmacotherapy. Expert consensus statement of the Polish Clinical Forum for Cardiovascular Imaging,Współczesna rola echokardiografii w monitorowaniu kardiotoksycznos̈ci leków przeciwnowotworowych. Stanowisko grupy ekspertów polskiego Klinicznego Forum Obrazowania Serca i Naczyń

Author

Piotrowski, G., Gawor, R., Gawor, Z., Szmit, S., Kasprzak, J. D., Mis̈kiewicz, Z., Opolski, G., Adam Torbicki, Krzakowski, M., Filipiak, K. J., Szyszka, A., Płońska-Gos̈ciniak, E., Szymański, P., Kostkiewicz, M., Miszalski-Jamka, T., Lipiec, P., Kukulski, T., Dziuk, M., Kochanowski, J., Scisło, P., Skowerski, M., Ga¸sior, Z., Walecki, J., Pasowicz, M., Ke¸pka, C., Wita, K., Klisiewicz, A., Hoffman, P., Podolec, P., Pruszczyk, P., Kowalski, M., and Mizia-Stec, K.

12. Recommendations of national team of cardiologic and oncologic supervision on cardiologic safety of patients with breast cancer. The prevention and treatment of cardiovascular complications in breast cancer,Rekomendacje krajowego zespołu nadzoru kardiologicznego i onkologicznego dotycza̧ce bezpieczeństwa kardiologicznego u chorych na raka piersi. Zapobieganie i postȩpowanie w powikłaniach sercowo-naczyniowych w raku piersi

Author

Opolski, G., Krzakowski, M., Szmit, S., Banach, J., Chudzik, M., Cygankiewicz, I., Drozdz, J., Filipiak, K. J., Grabowski, M., Kaczmarek, K., Kochman, J., Lewek, J., Maciej Krzakowski, Miśkiewicz, Z., Niwińska, A., Pieńkowski, T., Piestrzeniewicz, K., Sinkiewicz, W., Wranicz, J. K., and Zawilska, K.

13. Recommendations for diagnostics and therapy of adult patients with malignant primary bone tumors,Zalecenia postȩpowania diagnostyczno-terapeutycznego u chorych na pierwotne nowotwory złośliwe kości u dorosłych

Author

Rutkowski, P., Mazurkiewicz, T., Krzakowski, M., Ptaszyński, K., Klepacka, T., Grzesiakowska, U., Falkowski, S., Świtaj, T., Nowecki, Z. I., Morysiński, T., Spindel, J., Chmielik, E., Dragan, S., Nazar, J., Daniel Kotrych, Jan, S., Szumera-Ciećkiewicz, A., Szafrański, A., Szumiło, J., Karpik, M., Balcerkiewicz, K., Mazuryk, R., Jarosz, B., Rychłowska-Pruszyńska, M., Rzeszutko, M., Nowakowski, A., Rys, J., Olszewski, W. T., and Woźniak, W.

14. [Recommendations of National Team of Cardiologic and Oncologic Supervision on cardiologic safety of patients with breast cancer. The prevention and treatment of cardiovascular complications in breast cancer. The Task Force of National Consultants in Cardiology and Clinical Oncology for the elaboration of recommendations of cardiologic proceeding with patients with breast cancer]

Author

Opolski G, Krzakowski M, Sebastian Szmit, Banach J, Chudzik M, Cygankiewicz I, Drożdż J, Kj, Filipiak, Grabowski M, Kaczmarek K, Kochman J, Lewek J, and Task Force of National Consultants in Cardiology and Clinical Oncology

15. Pancreatic endocrine tumors - Management guidelines (recommended by the Polish Network of Neuroendocrine Tumors),Guzy endokrynne trzustki (zasady postȩpowania rekomendowane przez Polska̧ Sieć Guzów Neuroendokrynnych)

Author

Kos-Kudła, B., Bolanowski, M., Hubalewska-Dydejczyk, A., Krzakowski, M., Marek, B., Nasierowska-Guttmejer, A., Lampe, P., Sworczak, K., Bar-Andziak, E., Ćwikła, J., Dzielicki, J., Falconi, M., Foltyn, W., Gaciong, Z., Handkiewicz-Junak, D., Herder, W., Jarza̧b, B., Jeziorski, A., Kowalska, A., Kryszałowicz, B., Królicki, L., Krzyzanowska-Świniarska, B., Kunikowska, J., Kvols, L., O Toole, D., Matyja, V., Mełeń-Mucha, G., Milewicz, A., Nowak, A., Nowakowska-Duława, E., Omyła-Staszewska, J., Paja̧k, J., Rudzki, S., Sowiński, J., Starzyńska, T., Strzelczyk, J., Anhelli Syrenicz, Szawłowski, A., Tomaszewska, R., Waśko-Czopnik, D., Wroński, M., Zajȩcki, W., Zemczak, A., and Zgliczyński, W.

19. Consensus on medical treatment of non-small cell lung cancer

Author

Akehurst, Rl, Beinert, T., Crawford, J., Crino, L., Debus, J., Eckersberger, F., Fischer, J., Georgoulias, V., Gridelli, C., Hirsch, Fr, Jassem, J., Kosmidis, P., Krainer, M., Krzakowski, M., Manegold, C., Niklinski, J., Pirker, R., Pujol, Jl, Scagliotti, G., Thatcher, N., Tomek, S., Tonato, M., Nico van Zandwijk, Zielinski, Cc, Zochbauer, S., Zwitter, M., Central European Cooperative Onco, Vienna Med Assoc, and Advisory Comm Collaboration Ind Me

22. Recommendations for diagnostics and therapy of gastrointestinal stromal tumors (GIST) in 2010,Zasady postȩpowania diagnostyczno-terapeutycznego u chorych na nowotwory podścieliskowe przewodu pokarmowego (GIST)

Author

Piotr Rutkowski, Kulig, J., Krzakowski, M., Osuch, C., Siedlecki, J. A., Nasierowska-Guttmejer, A., Sygut, J., Limon, J., Jeziorski, A., Grzesiakowska, U., Ptaszyński, K., Słuszniak, J., Polkowski, W., Starosławska, E., Polkowski, M., Bȩbenek, M., Matłok, M., Urbańczyk, K., Olszewski, W., Głuszek, S., and Nowecki, Z. I.

25. Recommendations for diagnostics and therapy of gastrointestinal stromal tumors (GIST) in 2008,Zasady postepowania diagnostyczno-terapeutycznego u chorych na nowotwory podścieliskowe przewodu pokarmowego (GIST) w 2008 roku

Author

Ruka, W., Rutkowski, P., Kulig, J., Osuch, C., Krzakowski, M., Siedlecki, J. A., Nasierowska-Guttmejer, A., Sygut, J., Limon, J., Jeziorski, A., Grzesiakowska, U., Ptaszyński, K., Słuszniak, J., Polkowski, W., Stelmach, A., Starosławska, E., Polkowski, M., Marek Bebenek, Matłok, M., and Solska, E.

27. Consensus on medical treatment of non-small cell lung cancer

Author

Akehurst, R. L., Beinert, T., Crawford, J., Crino, L., Debus, J., Eckersberger, F., Fischer, J., Georgoulias, V., Gridelli, C., Hirsh, F. R., Jassem, J., Kosmidis, P., Krainer, M., Krzakowski, M., Manegold, Ch, Niklinski, J., Pirker, R., Pujol, J. L., Scagliotti, G., Thatcher, N., Tomek, S., Tonato, M., Nico van Zandwijk, Zielinski, C. C., Zöchbauer, S., and Zwitter, M.

28. Intensity-modulated radiation therapy as adjuvant treatment for local advanced malignant mesothelioma after pleuropneumonectomy - Report of two cases,Zastosowanie techniki intensywnej modulacji wia̧zki w leczeniu uzupełniaja̧cym chorych z miejscowo zaawansowanym złośliwym miȩdzybłoniakiem opłucnej poddanych zewna̧trzopłucnowej pleuropneumonektomii - opis dwóch przypadków

Author

Kowalski, D. M., Winiarczyk, K., Knetki-Wróblewska, M., Krzakowski, M., Orłowski, T., Katarzyna Zajda, Garmol, D., and Jaśkiewicz, P.

29. Recommendations: Nutrition in cancer patients,Konferencja uzgodnieniowa: problemy żywieniowe w polskiej onkologii

Author

Jarosz, J., Kapała, A., Kłȩk, S., Misiak, M., Bakinowska, B., Czaplińska, M., Czarnecki, M., Czarnuszewicz, M., Doboszyński, T., Dziura, R., Hetman, K., Kalinowska, B., Karwowska, K., Krawczyk, J., Kruczyk, I., Ewa Lange, Oczkowski, P., Ornat, M., Pałamarz-Zarczyńska, A., Piesoczyński, R., Smoliński, P., Stańczyk, M., Stryjowska, A., Tolińska, M., Wikłacz, R., Wollak-Lewandowska, M., Wylezał, I., Zmarzły, A., Jassem, J., and Krzakowski, M.

31. Estimation of prognostic and predictive factors for second-line therapy with docetaxel of locally advanced and metastatic non-small cell lung cancer patients,Ocena wartości czynników prognostycznych i predykcyjnych w leczeniu niedrobnokomórkowego raka płuca (NDRP) w stadium miejscowego zaawansowania lub rozsiewu z zastosowaniem docetakselu jako chemioterapii drugiej linii

Author

Krawczyk, P., Kowalski, D. M., Katarzyna Zajda, Knetki-Wróblewska, M., Wojas-Krawczyk, K., Szczyrek, M., Czukiewska, E., Krzakowski, M., and Milanowski, J.

38. Cost analysis of chemotherapy in advanced non-small cell lung cancer

Author

Skowron, A., Krzakowski, M., Brandys, J., Ma̧drzak, J., Rodryg Ramlau, Zukowska, H., Szczȩsny, T., Golecki, M., Wolf, H., and Jassem, J.

Subjects
niedrobnokomórkowy rak płuca, cost analysis, chemioterapia, analiza kosztów, chemotherapy, non-small cell lung cancer

39. Diagnostic and therapeutic guidelines for gastrointestinal neuroendocrine tumors (recommended by the Polish Network of Neuroendocrine Tumors),Zalecenia diagnostyczno-lecznicze w guzach neuroendokrynnych układu pokarmowego (rekomendowane przez Polska̧ Sieć Guzów Neuroendokrynnych)

Author

Kos-Kudła, B., Bolanowski, M., Handkiewicz-Junak, D., Jarza̧b, B., Królicki, L., Krzakowski, M., Kunikowska, J., Nasierowska-Guttmejer, A., Nowak, A., Rydzewska, G., Starzyńska, T., Szawłowski, A., Bar-Andziak, E., Ćwikła, J., Herder, W., Dzielicki, J., Falconi, M., Foltyn, W., Gaciong, Z., Hubalewska-Dydejczyk, A., Jeziorski, A., Kowalska, A., Kryszałowicz, B., Krzyzanowska-Świniarska, B., Kvols, L., O Toole, D., Lampe, P., Matyja, V., Mełén-Mucha, G., Milewicz, A., Nowakowska-Duława, E., Omyła-Staszewska, J., Paja̧k, J., Rudzki, S., Sowiński, J., Strzelczyk, J., Sworczak, K., Anhelli Syrenicz, Waśko-Czopnik, D., Wroński, M., Zemczak, A., and Zgliczyński, W.

40. Diagnostic and therapeutic guidelines for gastro-entero-pancreatic neuroendocrine neoplasms (recommended by the Polish Network of Neuroendocrine Tumours)

Author

Beata, Kos-Kudła, Jolanta, Blicharz-Dorniak, Janusz, Strzelczyk, Agata, Bałdys-Waligórska, Tomasz, Bednarczuk, Marek, Bolanowski, Agnieszka, Boratyn-Nowicka, Małgorzata, Borowska, Andrzej, Cichocki, Jarosław B, Ćwikła, Massimo, Falconi, Wanda, Foltyn, Daria, Handkiewicz-Junak, Alicja, Hubalewska-Dydejczyk, Barbara, Jarząb, Roman, Junik, Dariusz, Kajdaniuk, Grzegorz, Kamiński, Agnieszka, Kolasińska-Ćwikła, Aldona, Kowalska, Robert, Król, Leszek, Królicki, Maciej, Krzakowski, Jolanta, Kunikowska, Katarzyna, Kuśnierz, Paweł, Lampe, Dariusz, Lange, Anna, Lewczuk-Myślicka, Andrzej, Lewiński, Michał, Lipiński, Magdalena, Londzin-Olesik, Bogdan, Marek, Anna, Nasierowska-Guttmejer, Sergiusz, Nawrocki, Ewa, Nowakowska-Duława, Joanna, Pilch-Kowalczyk, Violetta, Rosiek, Marek, Ruchała, Lucyna, Siemińska, Anna, Sowa-Staszczak, Teresa, Starzyńska, Katarzyna, Steinhof-Radwańska, Krzysztof, Sworczak, Anhelli, Syrenicz, Andrzej, Szawłowski, Marek, Szczepkowski, Ewa, Wachuła, Wojciech, Zajęcki, Anna, Zemczak, Wojciech, Zgliczyński, Krzysztof, Zieniewicz, Kos-Kudla, B., Blicharz-Dorniak, J., Strzelczyk, J., Baldys-Waligorska, A., Bednarczuk, T., Bolanowski, M., Boratyn-Nowicka, A., Borowska, M., Cichocki, A., Cwikla, J. B., Falconi, M., Foltyn, W., Handkiewicz-Junak, D., Hubalewska-Dydejczyk, A., Jarzab, B., Junik, R., Kajdaniuk, D., Kaminski, G., Kolasinska-Cwikla, A., Kowalska, A., Krol, R., Krolicki, L., Krzakowski, M., Kunikowska, J., Kusnierz, K., Lampe, P., Lange, D., Lewczuk-Myslicka, A., Lewinski, A., Lipinski, M., Londzin-Olesik, M., Marek, B., Nasierowska-Guttmejer, A., Nawrocki, S., Nowakowska-Dulawa, E., Pilch-Kowalczyk, J., Rosiek, V., Ruchala, M., Sieminska, L., Sowa-Staszczak, A., Starzynska, T., Steinhof-Radwanska, K., Sworczak, K., Syrenicz, A., Szawlowski, A., Szczepkowski, M., Wachula, E., Zajecki, W., Zemczak, A., Zgliczynski, W., and Zieniewicz, K.

Subjects
Male, Gastro-entero-pancreatic neuroendocrine neoplasms, Disease Management, Medical Oncology, Pancreatic Neoplasms, Neuroendocrine Tumors, Endocrinology, Diagnosis, Humans, Female, Therapy, Poland, Societies, Medical, Gastrointestinal Neoplasms
Abstract

Progress in the diagnostics and therapy of gastro-entero-pancreatic (GEP) neuroendocrine neoplasms (NEN), the published results of new randomised clinical trials, and the new guidelines issued by the European Neuroendocrine Tumour Society (ENETS) have led the Polish Network of Neuroendocrine Tumours to update the 2013 guidelines regarding management of these neoplasms. We present the general recommendations for the management of NENs, developed by experts during the Third Round Table Conference - Diagnostics and therapy of gastro-entero-pancreatic neuroendocrine neoplasms: Polish recommendations in view of current European recommenda-tions, which took place in December 2016 in Żelechów near Warsaw. Drawing from the extensive experience of centres dealing with this type of neoplasms, we hope that we have managed to develop the optimal management system, applying the most recent achievements in the field of medicine, for these patients, and that it can be implemented effectively in Poland. These management guidelines have been arranged in the following order: gastric and duodenal NENs (including gastrinoma); pancreatic NENs; NENs of the small intestine and appendix, and colorectal NENs.

Published
2017

Catalog

Books, media, physical & digital resources
See catalog results